title: Drug-eluting stent: the "magic bullet" for prevention of restenosis?
abstract: The need for repeat interventions after initially successful PTCA due to restenosis has been called the "Archilles heel" of a percutaneous revascularization procedure. The incidence of restenosis varies between 20-50 % depending on the stent material, the presence of risk factors, and the location of vascular disease. Some risk factors such as diabetes have been clearly identified, others are currently debated. After years of failures trying to reduces restenosis rates, locally administered antiproliferative means have been shown to successfully inhibit excessive cell growth in response to PTCA. Local radiotherapy of in-stent restenosis results in a reduction of recurrent stenosis versus a conventional PTCA procedure. However, long-term evaluation indicated that restenosis may only be delayed with radiation therapy. Moreover, the restenosis rates were reduced, but the restenotic process was not eliminated. Coronary stents eluting the anti-proliferative agent rapamycin have demonstrated for the first time, that restenosis rates of zero percent are achievable after percutaneous revascularization procedures. Thus, it is intriguing to believe that the elimination of restenosis may have become reality. The purpose of this review is to discuss, whether a stent eluting drugs should be considered as the "magic bullet" for prevention of restenosis after PTCA.
authors.affiliation: Medizinische Universitätsklinik III, Abt für Kardiologie und Angiologie, Hugstetterstr 55, 79106 Freiburg i Br, Germany. hehrlein@med1.ukl.uni-freiburg.de
authors.forename: Christoph
authors.initials: C
authors.lastname: Hehrlein
authors.forename: Amina
authors.initials: A
authors.lastname: Arab
authors.forename: Christoph
authors.initials: C
authors.lastname: Bode
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D023903:Coronary Restenosis / Q000503:physiopathology / Q000517:prevention & control*; D016503:Drug Delivery Systems; D004867:Equipment Design; D006801:Humans; D011315:Preventive Medicine / Q000379:methods; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents
chemical_list: D020123:Sirolimus